Concepedia

Author

Jeffrey Schneider

Memorial Sloan Kettering Cancer Center

Also Known As

J G Schneider, J Schneider, J. G. Schneider, J. Schneider, J.G. Schneider, JEFFREY G SCHNEIDER, JEFFREY SCHNEIDER, Jeffrey G Schneider, Jeffrey G. Schneider, Jeffrey Gary Schneider

63

Publications

6.4K

Citations

21

H-Index

27

Concepts

All Affiliations

Memorial Sloan Kettering Cancer CenterWinthrop-University HospitalAstraZeneca (United Kingdom)Fondazione IRCCS Istituto Nazionale dei TumoriSungkyunkwan University
JS

About

Jeffrey Schneider is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

9

9

4.5K

2

Hepatology

2

2

1.6K

3

Obstetrics

2

2

91

4

Health Sciences

1

1

438

5

Immunology

1

1

17

Jeffrey Schneider

×

24

Publications

6.2K

Citations

20

H-Index

YearCitations

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen,

The Lancet

2019

2.1K

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba,

The Lancet

2019

1.2K

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen,

The Lancet Oncology

2020

662

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

Naiyer A. Rizvi, Byoung Chul Cho, Niels Reinmuth,

JAMA Oncology

2020

616

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue,

Journal of Hepatology

2020

438

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

Neal Ready, Anna F. Farago, Filippo de Braud,

Journal of Thoracic Oncology

2018

373

Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

Georgina V. Long, Scott S. Tykodi, Jeffrey Schneider,

Annals of Oncology

2018

200

Interactions among colony-stimulating factors, IL-1 beta, IL-6, and kit-ligand in the regulation of primitive murine hematopoietic cells.

Marcus O. Muench, Jeffrey Schneider, Michelle Moore

PubMed

1992

101

Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients

Mila B. Ortigoza, Hyunah Yoon, Keith Goldfeld,

JAMA Internal Medicine

2021

91

Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer.

John Crown, A. Kritz, Linda T. Vahdat,

Journal of Clinical Oncology

1993

70

Page 1